Alpha Cognition (ACOG) announced China Medical System new drug application for Zunveyl has been accepted by the National Medical Products Administration of China for review for the treatment of mild-to-moderate Alzheimer’s dementia. Alpha Cognition will rely on successful regulatory and commercial expertise of CMS in the Chinese market and will benefit financially from advances in China and other Asia territories. The company is eligible to receive regulatory, sales milestones, and royalties should Zunveyl be approved for marketing in China and other Asia territories.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACOG:
- Alpha Cognition Inc’s Strategic Developments and Market Potential Drive Buy Rating
- Alpha Cognition files to sell 2.09M common shares for holders
- Promising Preclinical Data on ALPHA-1062 Supports Buy Rating for Alpha Cognition
- Alpha Cognition shares preclinical data for TBI drug ALPHA-1062
- Alpha Cognition files to sell 2.375M common shares for holders